Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection

Phase 4

Conditions: Delayed Bleeding,
Quality of Ulcer
Healing Ulcer

Interventions: Drug: Ecabet

First Posted Date: 2011-03-03

Last Posted Date: 2011-03-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 90

Registration Number: NCT01308177

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis

Phase 3

Conditions: Nonsmall Cell Lung Cancer

Interventions: Radiation: Radiosurgery
Radiation: Observation

First Posted Date: 2011-02-23

Last Posted Date: 2011-02-23

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 176

Registration Number: NCT01301560

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: alpha blocker monotherapy
Drug: 5 alpha reductase inhibitor monotherapy
Drug: combination therapy

First Posted Date: 2011-02-23

Last Posted Date: 2019-12-02

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 308

Registration Number: NCT01301599

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

HER2 Circulating Tumor Cells in Gastric Cancer

Completed

Conditions: Gastric Cancer

First Posted Date: 2011-02-18

Last Posted Date: 2018-01-17

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 135

Registration Number: NCT01299688

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients

Phase 4

Terminated

Conditions: Graft vs Host Disease

Interventions: Drug: Itraconazole

First Posted Date: 2011-01-25

Last Posted Date: 2011-01-25

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 36

Registration Number: NCT01282879

Locations: 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Kyounggi-do, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of

and more 6 locations

Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: cetuximab/irinotecan/simvastatin

First Posted Date: 2011-01-24

Last Posted Date: 2013-06-14

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 52

Registration Number: NCT01281761

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2011-01-10

Last Posted Date: 2017-05-01

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 1070

Registration Number: NCT01273415

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Phase 2

Conditions: Metastatic Breast Cancer
Estrogen Receptor Positive Tumor
Breast Cancer Nos Premenopausal

Interventions: Drug: Fulvestrant plus Goserelin
Drug: Anastrozole plus Goserelin
Drug: Goserelin

First Posted Date: 2010-12-24

Last Posted Date: 2017-05-01

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 147

Registration Number: NCT01266213

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

Interventions: Drug: Simvastatin

First Posted Date: 2010-11-10

Last Posted Date: 2013-06-14

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 258

Registration Number: NCT01238094

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

Phase 2

Completed

Conditions: Advanced Gastric Cancer

Interventions: Drug: Docetaxel + Sunitinib
Drug: Docetaxel only

First Posted Date: 2010-11-10

Last Posted Date: 2013-04-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 116

Registration Number: NCT01238055

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy